Get the latest tech news
The case for clinical trial abundance
A series of short papers outlining reform possibilities for our nation's clinical trials
Jake Eberts and Allison Foss argue that to speed up medical research, regulators should allow competitive trial compensation, and Congress should ensure that participants do not lose eligibility for welfare benefits. Stuart Buck argues that Congress should require the FDA to publish redacted versions of complete response letters, allowing public health researchers and industry to learn more from each new drug application. Special thanks to all the authors of the policy memos, the attendees at the workshop, Trevan Locke, Nitya Sridhar, Milos Milijkovic, Randall Lutter, Michael Sklar and Clint Hermes for helpful comments throughout, and to Renaissance Philanthropy for support.
Or read this on Hacker News
